Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells
about
mTOR inhibitors effects on regulatory T cells and on dendritic cellsInducing and Administering Tregs to Treat Human DiseaseInduced regulatory T cells: mechanisms of conversion and suppressive potentialLow-dose interleukin-2 therapy: a driver of an imbalance between immune tolerance and autoimmunityRapamycin combined with anti-CD45RB mAb and IL-10 or with G-CSF induces tolerance in a stringent mouse model of islet transplantationCutting edge: PHLPP regulates the development, function, and molecular signaling pathways of regulatory T cellsAnti-CD154 mAb and rapamycin induce T regulatory cell mediated tolerance in rat-to-mouse islet transplantationCurrent status of immunomodulatory and cellular therapies in preclinical and clinical islet transplantation.Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells.Immunoregulatory functions of mTOR inhibition.Prediction and pathogenesis in type 1 diabetes.mTOR and GSK-3 shape the CD4+ T-cell stimulatory and differentiation capacity of myeloid DCs after exposure to LPS.Tolerance induction by exosomes from immature dendritic cells and rapamycin in a mouse cardiac allograft model.Foxp3+ Treg expanded from patients with established diabetes reduce Helios expression while retaining normal function compared to healthy individuals.How tolerogenic dendritic cells induce regulatory T cellsAddition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice.Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region.Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes.Acquired Omenn-like syndrome, a novel posttransplant autoaggression syndrome reversed by rapamycin.Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells.Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.Expression of PD-1 Molecule on Regulatory T Lymphocytes in Patients with Insulin-Dependent Diabetes Mellitus.Current and future immunomodulation strategies to restore tolerance in autoimmune diseases.Immunotherapy with Tolerogenic Dendritic Cells Alone or in Combination with Rapamycin Does Not Reverse Diabetes in NOD MiceCan We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?Targeting regulatory T cells in the treatment of type 1 diabetes mellitus.Type 1 diabetes genetic susceptibility and dendritic cell function: potential targets for treatment.Treg inducing adjuvants for therapeutic vaccination against chronic inflammatory diseasesLimitations of IL-2 and rapamycin in immunotherapy of type 1 diabetesRapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice.Anti-CD20 as the B-Cell Targeting Agent in a Combined Therapy to Modulate Anti-Factor VIII Immune Responses in Hemophilia a Inhibitor MiceNovel targeted therapies for autoimmunity.Clinical tolerance in allogeneic hematopoietic stem cell transplantation.Moving to tolerance: clinical application of T regulatory cellsThe Role of the PI3K Signaling Pathway in CD4(+) T Cell Differentiation and Function.The role of mechanistic target of rapamycin (mTOR) complexes signaling in the immune responses.mTOR signaling in T cell immunity and autoimmunity.Alteration of regulatory T cells in type 1 diabetes mellitus: a comprehensive review.Less is more: the detrimental consequences of immunosuppressive therapy in the treatment of type-1 diabetes.Strategies to accelerate immune recovery after allogeneic hematopoietic stem cell transplantation.
P2860
Q26744447-6F5CEE02-9917-4EF1-B960-27776C50D722Q26772723-77E80EBC-3663-440D-92B4-CF17E8B0E43FQ26823869-72BDCEC6-69FC-43E7-B8C0-D441C22811DFQ27008200-52D8D28D-29CC-4B23-97C0-71C63C3FE3D1Q27311412-BAA82FE5-BA5A-439B-BA55-EC538747F820Q28592480-B09CF250-4C5B-425F-8F03-EDCB00C484B3Q28752432-482B41A1-76B0-44E8-A74C-757E4B71CB3CQ30430008-E5F13989-0F9C-49C3-AF49-F86AD8080642Q33577441-94CFF0A5-38A0-48A5-B7BB-AE0861D135E0Q33761278-51C61F10-CB9A-4B23-B72D-C0EFA890926EQ33818896-92D8D236-D55E-4051-886B-303C622E8E4EQ33931904-52DE5064-04F9-462D-9AAD-08D584264B35Q34406142-CE88A981-2DF4-4BBC-855D-66C43384747FQ34586781-41818603-05B6-4F29-98EB-20DD70A1199AQ34631825-9C7CDA90-CE7E-43E5-8EE9-673DBFA66B2EQ34796651-BF031B61-3238-457F-A0FC-22422AF397E0Q35252405-1723E7AB-A839-470F-B3BA-71B6B1D8960FQ35405076-99F55491-4A16-4E3F-A83D-B77289659D34Q35666230-DD490121-AD35-4253-8249-2423B26B502DQ35743830-6EBD86F9-F326-4B87-B129-9B38C82301B8Q36182476-90EBDED0-74EF-40C7-8A3B-E45656ED27A9Q36184263-19087B16-3D69-401C-A728-2F6B0AFE338CQ36506677-81310648-6DE4-4528-8289-CC70008BA5C5Q36716382-0D06273F-8F25-43E0-A919-2D0A33E2EA83Q36827134-D3545449-639A-4570-95E8-FDCB2706FC6DQ37006155-359134D8-A997-4D4F-9CE0-EFDF93ABBAB6Q37098079-B2D60105-B034-4617-9F8B-611AA677A9CEQ37105550-97694CF6-9E15-4BE8-A4D3-5400B4F620B8Q37110531-7C315D07-D86F-4CF5-B0B4-3C5BD678BD68Q37141795-9D90DC32-B035-441D-A8DF-2669128DF990Q37434315-33CEA302-3300-4750-B74E-224AC0430ECFQ37614638-543B7A64-DBAD-4306-BF4F-34B92C773AD9Q37864697-67631818-9F06-4FC8-AE5A-A1B1A9E4CDE1Q37881151-6E84888D-378F-4FD9-94EA-64B4ED75C58DQ38035848-938948C8-0266-41C3-ADC7-7BEBE8D93D60Q38115702-0945B08B-151F-4345-B804-B63447DAE4D9Q38229078-06DEF5FD-BA81-43D3-83A1-95468C19039CQ38236300-4D323AC3-116F-4D46-8838-48CEDBA6201DQ38385236-D326AB94-B3E0-4877-9914-123CD8F973DEQ38640239-F7F64CD6-FC9D-4233-86FA-3B3CD2ABAC49
P2860
Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Rapamycin monotherapy in patie ...... CD25+FOXP3+ regulatory T-cells
@en
type
label
Rapamycin monotherapy in patie ...... CD25+FOXP3+ regulatory T-cells
@en
prefLabel
Rapamycin monotherapy in patie ...... CD25+FOXP3+ regulatory T-cells
@en
P2093
P2860
P50
P356
P1433
P1476
Rapamycin monotherapy in patie ...... CD25+FOXP3+ regulatory T-cells
@en
P2093
Antonio Secchi
Miriam Scirpoli
Paola Maffi
P2860
P304
P356
10.2337/DB08-0138
P407
P577
2008-06-16T00:00:00Z